Spotlight on microRNAs in allergy and asthma

Weidner, Julie; Bartel, Sabine; Kılıç, Ayşe; Zissler, Ulrich M.; Renz, Harald; Schwarze, Jürgen; Schmidt‐Weber, Carsten B.; Maes, Tania; Rebane, Ana; Krauss‐Etschmann, Susanne; Rådinger, Madeleine

doi:10.22541/au.159198584.42498314

Cited by 18 publications

(22 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As microRNAs are quite resistant to degradation, they can be easily be detected in body fluids including samples from the lower airways such as induced sputum. Along this line, deregulated microRNAs have been described in asthma as well as in allergic rhinitis (reviewed in 15 ). For example, levels of miR‐122‐5p were increased in sputum and serum of severe, uncontrolled asthmatics in comparison to healthy controls, 16 and miR‐223‐3p was associated with increased neutrophil counts and T‐helper cells of type 17 signalling in the sputum of asthmatics 17 .…”

Section: Introductionmentioning

confidence: 99%

Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy

Jakwerth

Chaker

Guerth

et al. 2021

Clin Experimental Allergy

View full text Add to dashboard Cite

Background Several microRNAs (miRs) have been described as potential biomarkers in liquid biopsies and in the context of allergic asthma, while therapeutic effects on the airway expression of miRs remain elusive. In this study, we investigated epigenetic miR‐associated mechanisms in the sputum of grass pollen‐allergic patients with and without allergen‐specific immunotherapy (AIT). Methods Induced sputum samples of healthy controls (HC), AIT‐treated and ‐untreated grass pollen‐allergic rhinitis patients with (AA) and without asthma (AR) were profiled using miR microarray and whole‐transcriptome microarray analysis of the same samples. miR targets were predicted in silico and used to identify inverse regulation. Local PGE2 levels were measured using ELISA. Results Two hundred and fifty nine miRs were upregulated in the sputum of AA patients compared with HC, while only one was downregulated. The inverse picture was observed in induced sputum of AIT‐treated patients: while 21 miRs were downregulated, only 4 miRs were upregulated in asthmatics upon AIT. Of these 4 miRs, miR‐3935 stood out, as its predicted target PTGER3, the prostaglandin EP3 receptor, was downregulated in treated AA patients compared with untreated. The levels of its ligand PGE2 in the sputum supernatants of these samples were increased in allergic patients, especially asthmatics, and downregulated after AIT. Finally, local PGE2 levels correlated with ILC2 frequencies, secreted sputum IL‐13 levels, inflammatory cell load, sputum eosinophils and symptom burden. Conclusions While profiling the sputum of allergic patients for novel miR expression patterns, we uncovered an association between miR‐3935 and its predicted target gene, the prostaglandin E3 receptor, which might mediate AIT effects through suppression of the PGE2‐PTGER3 axis.

show abstract

Section: Introductionmentioning

confidence: 99%

Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy

Jakwerth

Chaker

Guerth

et al. 2021

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRNAs) are small noncoding RNA molecules that are 18‐22 nucleotides long and play an important regulatory role in numerous immunological and inflammatory disorders, including allergic diseases (reviewed in Ref. [63]). Due to their surprisingly high stability, miRNAs may represent potential biomarkers for allergic diseases.…”

Section: Noninvasive and Minimally Invasive Diagnostics Of Allergic Airway Diseasesmentioning

confidence: 99%

Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases

Baumann

Untersmayr

Zissler

et al. 2021

Allergy

View full text Add to dashboard Cite

Allergic diseases of the (upper and lower) airways, the skin and the gastrointestinal tract, are on the rise, resulting in impaired quality of life, decreased productivity, and increased healthcare costs. As allergic diseases are mostly tissue‐specific, local sampling methods for respective biomarkers offer the potential for increased sensitivity and specificity. Additionally, local sampling using noninvasive or minimally invasive methods can be cost‐effective and well tolerated, which may even be suitable for primary or home care sampling. Non‐ or minimally invasive local sampling and diagnostics may enable a more thorough endotyping, may help to avoid under‐ or overdiagnosis, and may provide the possibility to approach precision prevention, due to early diagnosis of these local diseases even before they get systemically manifested and detectable. At the same time, dried blood samples may help to facilitate minimal‐invasive primary or home care sampling for classical systemic diagnostic approaches. This EAACI position paper contains a thorough review of the various technologies in allergy diagnosis available on the market, which analytes or biomarkers are employed, and which samples or matrices can be used. Based on this assessment, EAACI position is to drive these developments to efficiently identify allergy and possibly later also viral epidemics and take advantage of comprehensive knowledge to initiate preventions and treatments.

show abstract

“…85 The immune system in epithelial cells is posttranscriptional regulated by miRNAs. 144 Among others, miR-10a-5p has been identified to modulate AE targets. 145 L-type amino acid transporter 1 (LAT1) is critical for activating human and mouse T cells and its inhibition reveals a potential new target for AE treatment.…”

Section: New Developments In Systemic Treatment Optionsmentioning

confidence: 99%

“…CD300a expression has a downregulatory role in AE (mice), this could be an anti‐inflammatory strategy 85 . The immune system in epithelial cells is posttranscriptional regulated by miRNAs 144 . Among others, miR‐10a‐5p has been identified to modulate AE targets 145 .…”

Section: Therapymentioning

confidence: 99%

A new era of atopic eczema research: Advances and highlights

Hülpüsch

Weins

Traidl‐Hoffmann

et al. 2021

Allergy

View full text Add to dashboard Cite

Atopic eczema (AE) or atopic dermatitis (AD) is an inflammatory skin disease with involvement of genetic, immunological and environmental factors which are highly interconnected. 1,2 The heterogenic disease can be separated into different phenotypes and clinical presentations defined by the ethnicity, disease onset, disease severity, chronic vs acute, intrinsic vs extrinsic (IgE level), paediatric vs adult and inflammatory signature. [3][4][5] A common feature of all subtypes is a tremendous psychosocial burden for all patients with AE. 6 Prevalence varies by area and is reported to be 15-20% in children in Europe, persisting in up to 5-10% of adults. [7][8][9] Although severe cases are less abundant than mild or moderate disease pattern, 2% of affected children are severely suffering. 7,9 Therefore, AE remains to be a high and even increasing socio-economic burden in the United States and in Europe, 10,11 whereas slightly decreasing numbers were reported over the last few years in Japan. 12 Children often overcome atopic eczema, but set off on the so-called 'atopic march', that is begin a classic 'allergy career'. Scientifically, AE is a risk factor for the development of allergies. These are primarily type I allergies with clinical features such as hay fever and asthma. Allergies are increasingly becoming a widespread disease. Currently, almost every fourth person in Europe suffers from symptoms such as asthma or hay fever and the associated restrictions in everyday life or at work. For society, the reduced ability to perform at school, university and at work means great socio-economic damage.

show abstract

Spotlight on microRNAs in allergy and asthma

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 18 publications

References 77 publications

Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy

Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy

Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases

A new era of atopic eczema research: Advances and highlights

Contact Info

Product

Resources

About